The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Neurodegeneration In The Ageing Brain: How The Pathways Leading To Aggregated Protein Cause Disease
Funder
National Health and Medical Research Council
Funding Amount
$12,322,838.00
Summary
The team consists of eight highly experienced research scientists who are dedicated to solving the question of how the brain degenerates in the elderly when associated with the accumulation of certain proteins: e.g. A_ amyloid (Alzheimer�s disease) and PrP (Creutzfeldt-Jakob disease). Understanding the molecular pathways leading to the degeneration (loss of neuronal synapses) will permit the development of rational diagnostic and therapeutic interventions. Over the past five years the program ha ....The team consists of eight highly experienced research scientists who are dedicated to solving the question of how the brain degenerates in the elderly when associated with the accumulation of certain proteins: e.g. A_ amyloid (Alzheimer�s disease) and PrP (Creutzfeldt-Jakob disease). Understanding the molecular pathways leading to the degeneration (loss of neuronal synapses) will permit the development of rational diagnostic and therapeutic interventions. Over the past five years the program has identified several diagnostic and therapeutic avenues which are now being developed by the Pharmaceutical and Biotechnology industries. Much more research is still required for maximizing the chances of success using these approaches.Read moreRead less
The Causes, Treatment, And Prognosis Of Thyroid Disease
Funder
National Health and Medical Research Council
Funding Amount
$190,445.00
Summary
The thyroid gland controls body metabolism and is crucial to life. Disorders of the thyroid place a severe burden on the health system. Yet despite this, much is unknown about the causes, optimal treatments, and prognosis of thyroid disease. In this NHMRC Early Career Fellowship, Don aims to advance knowledge and improve treatments of these common conditions, focusing on thyroid cancer, Graves’ disease, and Hashimoto’s thyroiditis.
Hypoxic Regulation Of Integrin Beta1 During Mucosal Wound Healing
Funder
National Health and Medical Research Council
Funding Amount
$318,104.00
Summary
Very little is currently known about how healing is initiated in the gut. Further understanding may allow us to improve the treatment of IBD wounding and allow new therapies to control the disease. Our work examines the role of an adhesion protein, ?1 integrin, important in the repair of intestinal wounds. Understanding the mechanisms of how ?1 integrin is involved in wound healing may allow the rational design of therapies to aid or accelerate wound healing in inflammatory disease.
How Should Moderate Iron Overload In Haemochromatosis Be Managed?
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
My PhD studies hereditary haemochromatosis which causes iron accumulation in the body which can be treated by removing blood. Whilst those with very high iron levels require treatment, it is not clear if those with only moderately raised iron also need treatment. If this study shows there is no difference in outcomes between the groups treatment to normalise body iron versus those who do not normalise body iron, this will change current practice.
Novel Treatment Approaches To Prevent Joint Fusion In Ankylosing Spondylitis
Funder
National Health and Medical Research Council
Funding Amount
$477,440.00
Summary
Ankylosing spondylitis (AS) is a form of arthritis targeting the spine and pelvis that causes uncontrolled bone formation resulting in complete joint fusion, severe disability and even death for which no therapies are currently available. Using a mouse model that closely replicates the human disease we will characterise the changes causing this joint fusion and identify possible new targets to develop novel treatments.
Development And Evaluation Of Novel Fetal Haemoglobin Inducers For The Therapy Of Beta-thalassaemia
Funder
National Health and Medical Research Council
Funding Amount
$288,899.00
Summary
The most important haemoglobinopathies from the clinical point of view are the beta-thalassaemias, sickle cell disease (SCD), HbE disease and the interactions between them. These beta-haemoglobinopathies are the result of mutations in the beta-globin gene, causing beta-globin chain synthesis that is abnormal, low or absent leading to life-threatening severe anaemia, and blood transfusion-dependency for life. An alternative approach to the therapy of beta-thalassemia is to reactivate fetal haemog ....The most important haemoglobinopathies from the clinical point of view are the beta-thalassaemias, sickle cell disease (SCD), HbE disease and the interactions between them. These beta-haemoglobinopathies are the result of mutations in the beta-globin gene, causing beta-globin chain synthesis that is abnormal, low or absent leading to life-threatening severe anaemia, and blood transfusion-dependency for life. An alternative approach to the therapy of beta-thalassemia is to reactivate fetal haemoglobin (HbF) synthesis. Some chemical agents have been identified to induce HbF and significantly reduce the need for blood transfusion in some thalassaemia patients, while in SCD patients it can ameliorate the clinical symptoms. Despite a number of clinical trials investigating the potential of HbF-inducing agents, many of these drugs have low efficacy, specificity, and cytotoxicity. There is therefore an urgent need to identify novel pharmacological agents with greater efficacy and reduced toxicity. Without a clear understanding of the underlying mechanism(s) involved in the induction of HbF, it is virtually impossible to focus on any molecular target. A promising approach is the use of chemical libraries in a high-throughput (HTP) screening to identify positive regulators of gene products. Our research group created an assay that has allowed us for the first time to perform a side-by-side comparison of several previously described fetal hemoglobin inducers including 2000 existing pharmaceuticals used by patients unrelated to thalassaemia. The screen identified a distinct group of compounds that induced the gamma-globin promoter in primary and secondary screens. The identification of novel inducers of HbF warrants further investigation as alternative therapies for beta-thalassemia. This project will evaluate novel inducers of HbF in our thalassaemia mouse model and provide early 'proof-of-concept' and enable the initiation of preclinical and clinical studies.Read moreRead less
Unraveling IL-1F7: A Neglected IL-1 Family Member With Big-Stage Potential
Funder
National Health and Medical Research Council
Funding Amount
$349,590.00
Summary
Cytokines are messenger proteins used by most cells of the body. Since their role as master regulators of many biological processes was discovered, cytokines have enjoyed the limelight of biomedical research. Anti-inflammatory cytokines are particularly coveted as they could replace side effect-prone anti-inflammatory drugs like aspirin. We identified an anti-inflammatory cytokine (IL-1F7) and revealed its protective activity in common, severe diseases like myocardial infarction. We will now exp ....Cytokines are messenger proteins used by most cells of the body. Since their role as master regulators of many biological processes was discovered, cytokines have enjoyed the limelight of biomedical research. Anti-inflammatory cytokines are particularly coveted as they could replace side effect-prone anti-inflammatory drugs like aspirin. We identified an anti-inflammatory cytokine (IL-1F7) and revealed its protective activity in common, severe diseases like myocardial infarction. We will now explore how IL-1F7 exerts is protective properties.Read moreRead less
Mitochondrial Iron Overload And Friedreich's Ataxia: The Role Of Frataxin In Iron And Haem Metabolism
Funder
National Health and Medical Research Council
Funding Amount
$606,000.00
Summary
Friedreich's ataxia (FA) is due to the lack of a protein known as frataxin. A variety of studies using Baker's yeast and conditional frataxin knockout (KO) mice have shown that deletion of frataxin leads to the accumulation of toxic iron in their mitochondrion. More recently, a variety of studies have shown that FA patients have iron-loading within their mitochondrion. Iron in the highly redox active environment of the mitochondrion could contribute to the generation of cytotoxic radicals that c ....Friedreich's ataxia (FA) is due to the lack of a protein known as frataxin. A variety of studies using Baker's yeast and conditional frataxin knockout (KO) mice have shown that deletion of frataxin leads to the accumulation of toxic iron in their mitochondrion. More recently, a variety of studies have shown that FA patients have iron-loading within their mitochondrion. Iron in the highly redox active environment of the mitochondrion could contribute to the generation of cytotoxic radicals that cause severe damage. Further, cells deficient in frataxin are sensitive to oxidant stress and Fe chelators rescue oxidant-mediated death of cells from FA patients. Indeed, free radical scavengers have shown to be of use in the treatment of this disease. Studies in DR's lab during this NHMRC grant have shown that frataxin is down-regulated by erythroid differentiation or the haem precursor, protoporphyrin IX (BLOOD 2002;99:3813-22). These data indicate a role for frataxin in Fe metabolism and the pathogenesis of FA. In this study we will continue to examine the role of frataxin in the way cells handle Fe using experimental models developed under the current NHMRC grant. These include transfected cell lines with low frataxin expression generated using an expression vector containing anti-sense frataxin cDNA. Further we obtained the frataxin conditional KO mouse and generated a breeding colony. These animals display many of the pathological features of FA and are the best current model of the disease. Indeed, they will be critical for assessing the role of frataxin in Fe metabolism and as a model to test the ability of Fe-binding drugs to prevent the pathology observed. We designed lipid-soluble chelators that can enter the mitochondrion to bind Fe (Biochim Biophys Acta 2001;1536:133-140) and these ligands will be tested to prevent disease progression in the KO mice. This exciting research is crucial for understanding the pathogenesis of FA and in creating new therapies.Read moreRead less
Are Chondrocytes The Target Cells Of Glucocorticoid Therapy In Autoimmune Arthritis?
Funder
National Health and Medical Research Council
Funding Amount
$544,619.00
Summary
Glucocorticoids (GCs) are widely used for their potent anti-inflammatory and immunomodulatory effects due to the effects GCs on immune cells or synovial fibroblasts. Recently, we have made the exciting discovery that arthritis mice with glucocorticoid receptor knock-out in chondrocyte are completely resistant to glucocorticoid treatment. This study will identify the mechanisms underlying these hormonal effects with the aim to find new targets for efficient treatments for arthritis.
Mitochondrial Function And The Role Of PGC-1a In Parkinson�s Disease
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degen ....Parkinson's Disease is the second most common neurodegenerative disease in Australia. Insights into the mechanisms causing Parkinson's disease may lead to therapeutic advances. This project will examine PGC-1a, a co-factor involved in the regulation of cellular energy metabolism, and examine it's role in the development of neuro-degeneration in Parkinson's disease. We aim to provide further understanding of cellular function in Parkinson's disease, and assist in therapeutic trials in neuro-degeneration.Read moreRead less